Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.420
+0.020 (0.83%)
At close: Aug 26, 2025, 4:00 PM
2.460
+0.040 (1.65%)
After-hours: Aug 26, 2025, 6:51 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 8 analysts that cover MRVI stock have a consensus rating of "Hold" and an average price target of $5.84, which forecasts a 141.32% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $10.
Price Target: $5.84 (+141.32%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for MRVI stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +106.61% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +313.22% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -17.36% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +106.61% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | +3.31% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
195.57M
from 259.19M
Decreased by -24.54%
Revenue Next Year
209.71M
from 195.57M
Increased by 7.23%
EPS This Year
-0.32
from -1.05
EPS Next Year
-0.22
from -0.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 213.7M | 234.2M | |||
| Avg | 195.6M | 209.7M | |||
| Low | 181.7M | 188.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -17.6% | 19.7% | |||
| Avg | -24.5% | 7.2% | |||
| Low | -29.9% | -3.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.24 | -0.07 | |||
| Avg | -0.32 | -0.22 | |||
| Low | -0.44 | -0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.